Lupus & antiphospholipid syndrome
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort
Authors' conclusion
aPLs, especially IgG isotype and LA, are independently associated with diverse HVD in SLE.
Study context
- Population
- Consecutive patients with SLE at Peking Union Medical College Hospital, April 1999–December 2024, echocardiography per clinical indication
- Participants
- 508 patients
- Exposure
- aPL-positive vs aPL-negative patients with SLE
- Outcome
- Heart valve disease (HVD)
Methodological detailsconsecutive patients, single-centre, logistic regression
- Consecutive patients
- Single-centre
- Logistic regression
Main finding
As reported in the abstract
HVD
P = 0.010
Observational data: associations, not effects.
Further findings
Valve thickening
P = 0.028
Regurgitation
P < 0.001
Vegetations
P < 0.001
Stenosis
P = 0.008
| Outcome | OR | P value |
|---|---|---|
| Anticardiolipin-IgG associationsAnticardiolipin-IgG · HVD | 2.484 | P = 0.003 |
| Anticardiolipin-IgG associationsAnticardiolipin-IgG · mitral lesions | 4.156 | P < 0.001 |
| Anticardiolipin-IgG associationsAnticardiolipin-IgG · valve thickening | 2.255 | P = 0.011 |
| Anticardiolipin-IgG associationsAnticardiolipin-IgG · regurgitation | 2.121 | P = 0.014 |
| Anti-β2 glycoprotein I-IgG and valve stenosis | 11.209 | P = 0.022 |
| LA associationsLA · valve vegetations | 8.659 | P < 0.001 |
| LA associationsLA · interventional/surgical indications | 6.868 | P = 0.005 |
HVD prevalence, all SLE
- HVD
- 27.4%
- Aortic valve
- 17.3%
- Mitral valve
- 11.2%
- Thickening
- 19.5%
- Regurgitation
- 15.9%
Anti-β2 glycoprotein I-IgG and valve stenosis
- Anti-β2 glycoprotein I-IgG showed similar associations
Original publication
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort. Lupus Sci Med. Published 19 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →